


Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	To be assigned
				Filing Date	December 1, 2003 10/727,-
				First Named Inventor	Embden et al.
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	2183-6192US

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>2</sup> - Number <sup>4</sup> - Kind Code <sup>3</sup> (if known)				
		#0 564 307 A1	10/1893	Europe		
		#06025000	01/1894	Japan		
		#WO 95/12408	05/1995	PCT		
		#WO 97/04792	02/1997	PCT		
		#2 311 727 A	10/1897	United Kindgom		

Examiner Signature	<i>V. A. Johnson</i>	Date Considered	<i>9-14-2006</i>
-----------------------	----------------------	--------------------	------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	To be assigned
Filing Date	December 1, 2003
First Named Inventor	Embden et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2183-6192IIS

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
VA		#Notification of Transmittal of the International Preliminary Examination Report.	
VA		#GENELL et al., Protease Inhibitors in Plasma and Faecal Extracts from Patients with Active Inflammatory Bowel Disease, June 1986, pp. 598-604.	
↑		#HUTTON et al., Mucolysis of the colonic mucus barrier by faecal proteinases: inhibition by interacting polyacrylate, March 1990, pp. 265-271.	
		#FRENKEL et al., Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes, September 1987, pp. 1207-1212.	
		#KEILOVA et al., Naturally occurring inhibitors of intracellular proteinases, 1977, pp. 1873-1881.	
		#YAHAGI et al., Manufacture of soybean extracts containing trypsin inhibitors for controlling skin disorders, July 8, 1997, Abstract No. 127:126636.	
		#PEARCE et al., Archives of Biochemistry and Biophysics, February 1982, Vol. 213, No. 2, pp. 456-62.	
		#RODIS et al., Plant Physiol., 1984, Vol. 74, pp. 907-11.	
		#RADOEV et al., Nauchni Tr., Vissh Inst. Khranitelna Vkusova Prom. Plovdiv, 1964, Vol. 11, pp. 265-70.	
VA		#WOROWSKI et al., Acta Pol. Pharm., 1973, Vol. 30, No. 4, pp. 453-57.	

Examiner  
Signature

V. Afrem

Date  
Considered

9-14-2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/716,612

Filed: November 20, 2000

For: METHODS AND MEANS FOR PREVENTING OR TREATING INFLAMMATION OR PRURITIS, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.